2022 IMW | 中国专家国际性再发音,精彩纷呈汇总,别错过

  • A+
所属分类:医疗资讯

2022 IMW | 中国专家国际性再发音,精彩纷呈汇总,别错过 。
印度的natco马法兰盘Melphalan摘 要:。2022 IMW | 中国专家国际性再发音,精彩纷呈汇总,别错过

2022年第一8届国际性骨髓瘤讨论会(IMW)将于2022年9月8-11日在匈牙利美泉宫举办,大会由国际性骨髓瘤学好(IMS)举办,专注于推动窦汇区骨髓癌和有关浆细胞病症的全新开创性科学研究和临床医学沟通交流。伴随着我国基本医科学研究与临床医学医科学研究迅猛发展,愈来愈多的中国专家在国际学术会议上展示风彩,2021年又有哪一些中国专家走上了IMW的平台呢?一起来看下。

2021 IMW 中国专家Oral归纳01 引言号:OAB-011文章标题:Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single cell level.第一【微信号码:yaodaoyaofang】:Yuting Yan企业:我国医科大学课程学校血液病医院02 引言号:OAB-021文章标题:BCMA-specific ADC MEDI2228 and Daratumumab induce synergistic myeloma cytotoxicity via enhanced IFN-driven innate immune responses and expression of CD38 and NKG2D ligands.第一【微信号码:yaodaoyaofang】:Lijie Xing单位:山东省第一医科大附设省立医院03 引言号:OAB-039文章标题:Distinct immunoglobulin heavy-chain variable gene repertoire and its clinical relevance in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.第一【微信号码:yaodaoyaofang】:Yuting Yan企业:我国医科大学课程学校血液病医院2021 IMW 中国专家Poster归纳01 引言号:P-026文章标题:A prognostic staging system for light-chain amyloidosis using hepatic and renal indicator data of 1064 Chinese patients.第一【微信号码:yaodaoyaofang】:燕玮企业:吉林大学附设盛京医院02 引言号:P-027文章标题:Development of an artificial intelligence diagnostic model based on routine laboratory results and echocardiography for the early diagnosis of light chain amyloidosis.第一【微信号码:yaodaoyaofang】:燕玮企业:吉林大学附设盛京医院03 引言号:P-081文章标题:A novel circulating miRNA involved in T cell senescence of multiple myeloma patients.第一【微信号码:yaodaoyaofang】:Xiaojing Wei企业:我国医科大学课程学校血液病医院04 引言号:P-088文章标题:Indirubin-3’-monoxime acts as an alternative proteasome inhibitor and confers new regimens for the treatment of multiple myeloma.第一【微信号码:yaodaoyaofang】:Zhen Yu企业:我国医科大学课程学校血液病医院05 引言号:P-141文章标题:Lenalidomide versus Thalidomide or Bortezomib as maintenance regimen for nontransplant patients with multiple myeloma: multi-center real world experiences in China.第一【微信号码:yaodaoyaofang】:Zhe Zhuang单位:北京协和06 引言号:P-142文章标题:Ixazomib versus Lenalidomide or Ixazomib and Lenalidomide combination as maintenance regimen for patients with multiple myeloma: interim analysis of a multi-center prospective study in China.第一【微信号码:yaodaoyaofang】:Zhe Zhuang单位:北京协和07 引言号:P-160文章标题:Efficacy and safety of induction therapy with IAd versus IRd regimen in fragile elderly patients with newly diagnosed multiple myeloma---results of a prospective multicenter clinical trail.第一【微信号码:yaodaoyaofang】:鲍立企业:北京积水潭医院08 引言号:P-163文章标题:Efficacy and Safety of Da2022 IMW | 中国专家国际性再发音,精彩纷呈汇总,别错过ratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Chinese Patients with Newly Diagnosed Multiple Myeloma: OCTANS.第一【微信号码:yaodaoyaofang】:傅卫军企业:上海长征医院09 引言号:P-174文章标题:Clinical study of bortezomib-based regimens of BCD, PAD and VDD for newly diagnosed multiple myeloma——An analysis of 400 cases in a single center of China.第一【微信号码:yaodaoyaofang】:Shuhui Deng单位:我国医科大学课程学校血液病医院10 引言号:P-192文章标题:Circularly Permuted TRAIL (CPT) Combined with Thalidomide and Dexamethasone in Patientswith Relapsed/Refractory Multiple Myeloma: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.第一【微信号码:yaodaoyaofang】:陈文明校园:首都医科大附设北京朝阳医院11 引言号:P-211文章标题:Phase 2 MARCH Study: ATG-010 plus Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IM2022 IMW | 中国专家国际性再发音,精彩纷呈汇总,别错过iD) and a Proteasome Inhibitor (PI).第一【微信号码:yaodaoyaofang】:邱录贵企业:我国医科大学课程学校血液病医院若有忽略,请给大家留言板留言。马法兰盘(ALPHALAN)Alphalan Melphalan Tablets 2mg 馬法蘭片 马法兰 药道全世界,助推性命。印度的全世界海淘药店:。

  • 微信咨询
  • 这是我的微信扫一扫
  • weinxin
  • WhatsApp 沟通
  • 手机扫一扫二维码
  • weinxin

发表评论

:?: :razz: :sad: :evil: :!: :smile: :oops: :grin: :eek: :shock: :???: :cool: :lol: :mad: :twisted: :roll: :wink: :idea: :arrow: :neutral: :cry: :mrgreen: